The EHA research Roadmap: Immune-based therapies for hematological malignancies

Hermann Einsele*, Javier Briones, Fabio Ciceri, Irene García Cadenas, Fred Falkenburg, Natacha Bolaños, H. M.Mirjam Heemskerk, Roch Houot, Michael Hudecek, Franco Locatelli, Kate Morgan, Emma C. Morris, Michael O’Dwyer, Jordi Gil Sierra, Marcel van den Brink, Arjan A. van de Loosdrecht

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review


In 2016, the European Hematology Association (EHA) published the EHA Roadmap for European Hematology Research1 aiming to highlight achievements in the diagnostics and treatment of blood disorders, and to better inform European policy makers and other stakeholders about the urgent clinical and scientific needs and priorities in the field of hematology. Each section was coordinated by 1–2 section editors who were leading international experts in the field. In the 5 years that have followed, advances in the field of hematology have been plentiful. As such, EHA is pleased to present an updated Research Roadmap, now including 11 sections, each of which will be published separately. The updated EHA Research Roadmap identifies the most urgent priorities in hematology research and clinical science, therefore supporting a more informed, focused, and ideally a more funded future for European Hematology Research. the 11 EHA Research Roadmap sections include normal hematopoiesis; malignant lymphoid diseases; malignant myeloid diseases; anemias and related diseases; platelet disorders; blood coagulation and hemostatic disorders; transfusion medicine; infections in hematology; hematopoietic stem cell transplantation; CAR-T and Other cell-based immune therapies; and gene therapy.
Original languageEnglish
Article numbere642
Early online date2021
Publication statusE-pub ahead of print - 2021

Cite this